111 related articles for article (PubMed ID: 36893574)
1. Symptoms, symptom clusters and associated factors among cancer patients receiving immune checkpoint inhibitor therapy: A cross-sectional survey.
Feng LN; He J; Feng LX; Li Y; Li J; Chen C
Eur J Oncol Nurs; 2023 Apr; 63():102288. PubMed ID: 36893574
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
Steffen McLouth LE; Lycan TW; Levine BJ; Gabbard J; Ruiz J; Farris M; Grant SC; Pajewski NM; Weaver KE; Petty WJ
Clin Lung Cancer; 2020 May; 21(3):255-263.e4. PubMed ID: 31917067
[TBL] [Abstract][Full Text] [Related]
3. Administration of Immune Checkpoint Inhibitors Near the End of Life.
Bloom MD; Saker H; Glisch C; Ramnaraign B; George TJ; Markham MJ; Kelkar AH
JCO Oncol Pract; 2022 Jun; 18(6):e849-e856. PubMed ID: 35254868
[TBL] [Abstract][Full Text] [Related]
4. Association of Inflammatory Cytokines With the Symptom Cluster of Pain, Fatigue, Depression, and Sleep Disturbance in Chinese Patients With Cancer.
Ji YB; Bo CL; Xue XJ; Weng EM; Gao GC; Dai BB; Ding KW; Xu CP
J Pain Symptom Manage; 2017 Dec; 54(6):843-852. PubMed ID: 28797869
[TBL] [Abstract][Full Text] [Related]
5. Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors.
Krishnan M; Kasinath P; High R; Yu F; Teply BA
JCO Oncol Pract; 2022 Jan; 18(1):e175-e182. PubMed ID: 34351819
[TBL] [Abstract][Full Text] [Related]
6. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
7. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
11. Symptom clusters and related factors in oesophageal cancer patients 3 months after surgery.
Guo M; Wang C; Yin X; Nie L; Wang G
J Clin Nurs; 2019 Oct; 28(19-20):3441-3450. PubMed ID: 31162849
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer.
Muchnik E; Loh KP; Strawderman M; Magnuson A; Mohile SG; Estrah V; Maggiore RJ
J Am Geriatr Soc; 2019 May; 67(5):905-912. PubMed ID: 30698276
[TBL] [Abstract][Full Text] [Related]
13. Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients.
Wang XS; Wang Y; Guo H; Mendoza TR; Hao XS; Cleeland CS
Cancer; 2004 Oct; 101(8):1890-901. PubMed ID: 15386315
[TBL] [Abstract][Full Text] [Related]
14. [Identification and validation of symptom clusters in patients with hepatocellular carcinoma].
Cho MS; Kwon IG; Kim HS; Kim K; Ryu E
J Korean Acad Nurs; 2009 Oct; 39(5):683-92. PubMed ID: 19901498
[TBL] [Abstract][Full Text] [Related]
15. Symptom Clusters and Quality of Life in Gastric Cancer Patients Receiving Chemotherapy.
Fu L; Feng X; Jin Y; Lu Z; Li R; Xu W; Chang VT; Hu Y; Ye X
J Pain Symptom Manage; 2022 Feb; 63(2):230-243. PubMed ID: 34537311
[TBL] [Abstract][Full Text] [Related]
16. Symptom burden survey and symptom clusters in patients with cervical cancer: a cross-sectional survey.
Zhou KN; Wang Y; Xie Y; Yang SH; Liu SY; Fang YH; Zhang Y
Support Care Cancer; 2023 May; 31(6):338. PubMed ID: 37191783
[TBL] [Abstract][Full Text] [Related]
17. The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy.
Jackson-Carroll N; Johnson C; Tawbi H; Wang XS; Whisenant M
Semin Oncol Nurs; 2024 Feb; 40(1):151574. PubMed ID: 38220519
[TBL] [Abstract][Full Text] [Related]
18. ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study.
Iivanainen S; Alanko T; Peltola K; Konkola T; Ekström J; Virtanen H; Koivunen JP
J Cancer Res Clin Oncol; 2019 Mar; 145(3):765-774. PubMed ID: 30666409
[TBL] [Abstract][Full Text] [Related]
19. Study on sentinel symptoms and influencing factors of postoperative chemotherapy in patients with gastric cancer.
Wei L; Lv F; Luo C; Fang Y
Eur J Oncol Nurs; 2023 Jun; 64():102318. PubMed ID: 37167842
[TBL] [Abstract][Full Text] [Related]
20. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
Chalker C; Voutsinas JM; Wu QV; Santana-Davila R; Hwang V; Baik CS; Lee S; Barber B; Futran ND; Houlton JJ; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Eaton KD; Rodriguez CP
Cancer Med; 2022 Nov; 11(22):4104-4111. PubMed ID: 35349227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
